ABSTRACT
BACKGROUND: This study aimed to test the safety of using perioperative high-dose-rate brachytherapy (PHDRB) in resected head and neck cancer. METHODS: From 2000 to 2008, 97 patients received PHDRB after complete macroscopic resection. Group 1 (previously irradiated patients) received 32 to 40 Gray (Gy) of PHDRB in 8 to 10 twice-daily (bid) treatments (R0-R1 resections). Group 2 (unirradiated patients) received 16 to 24 Gy of PHDRB in 4 to 6 bid treatments (R0-R1 resections) followed by external beam irradiation (EBRT) of 45 Gy/25 daily fractions ± concomitant chemotherapy. RESULTS: The median follow-up was 4.3 years. The cumulative hazard of 2-year grade ≥ 3 complications in group 1 was 45.9%, and the rate of grade ≥ 3 complications in group 2 was 24.6%. Actuarial locoregional control at 2 and 5 years for group 1 was 60.9% and for group 2, 84.1% and 79.4%. CONCLUSIONS: Complications and locoregional failure rates were similar to those reported in the reference standards despite a much smaller treatment volume.
Subject(s)
Brachytherapy , Carcinoma, Squamous Cell/therapy , Head and Neck Neoplasms/therapy , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Squamous Cell/mortality , Chemoradiotherapy, Adjuvant , Cisplatin/administration & dosage , Female , Follow-Up Studies , Head and Neck Neoplasms/mortality , Humans , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local , Paclitaxel/administration & dosage , Radiotherapy DosageABSTRACT
PURPOSE: To determine the impact of a set of patient, tumor, and treatment factors on toxicity and outcome in patients with head-and-neck squamous cell cancer treated with surgical resection and perioperative high-dose rate brachytherapy (PHDRB) alone (single-modality [SM] group) (n = 46) or PHDRB combined with postoperative radiation or chemoradiation (combined-modality [CM] group) (n = 57). METHODS AND MATERIALS: From 2000 to 2008, 103 patients received PHDRB after complete macroscopic resection. SM patients received 32 or 40 Gy of PHDRB in 8 or 10 twice-daily treatments for R0 and R1 resections. CM patients received 16 or 24 Gy of PHDRB in 4 or 6 twice-daily treatments for R0 and R1 resections, followed by external radiation of 45 Gy in 25 fractions with or without concomitant chemotherapy. RESULTS: Grade ≥4 complications according to the Radiation Therapy Oncology Group were more frequent in the SM group than in the CM group (p = 0.024). Grade ≥3 and ≥4 complications increased with the antecedent of prior irradiation (p = 0.032 and p = 0.006, respectively) and with TV(150) values of 13 mL or greater (p = 0.032 and p = 0.032, respectively). After a median follow-up of 34.8 and 60.8 months for SM and CM patients, respectively, patients with high-risk margins had a 9-year local control rate of 68.0% whereas patients with wider margins had a 9-year local control of 93.7% (p = 0.045). Patients with primary and recurrent tumors had 9-year actuarial locoregional control rates of 81.8% and 54.2%, respectively (p = 0.003). Patients with lymph-vascular space invasion (LVSI)-positive and LVSI-negative tumors had 9-year distant control rates of 62.8% and 81.6%, respectively (p = 0.034). Disease-free survival rates decreased in recurrent cases (p = 0.006) as well as in LVSI-positive patients (p = 0.035). CONCLUSIONS: The complications observed are largely attributable to the antecedent of prior irradiation but can possibly be minimized by meticulous mapping and exhaustive planning to reduce TV(150) values. Patients with high-risk margins, LVSI-positive status, and recurrent disease have a higher risk of treatment failure, and therefore risk-directed treatment strategies are required.
Subject(s)
Brachytherapy/adverse effects , Carcinoma, Squamous Cell/therapy , Head and Neck Neoplasms/therapy , Neoplasm Recurrence, Local/therapy , Adult , Aged , Aged, 80 and over , Analysis of Variance , Brachytherapy/methods , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Chemoradiotherapy/adverse effects , Chemoradiotherapy/methods , Combined Modality Therapy/adverse effects , Combined Modality Therapy/methods , Disease-Free Survival , Female , Follow-Up Studies , Head and Neck Neoplasms/mortality , Head and Neck Neoplasms/pathology , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Radiotherapy Dosage , Squamous Cell Carcinoma of Head and Neck , Survival Rate , Treatment FailureABSTRACT
PURPOSE: To explore the feasibility of a intraoral mold high-dose rate (HDR) brachytherapy in the treatment of tumors arising in the maxillary antrum after maxillectomy and to describe the dosimetric profile of HDR brachytherapy in such an unusual location. METHODS AND MATERIALS: A customized mold with four 6-French catheters was designed and produced in transparent acrylic resin. The catheters formed a soft loop that allowed the passage of the HDR source. CT-based dose evaluation in several volumes of interest, including the gross tumor volume (GTV) and several organs at risk (OARs), such as the skin of the cheek, eyeball, lens, optic nerve, optic chiasm, and spinal cord was performed. RESULTS: Treatments were delivered uneventfully. A favorable OAR/GTV ratio was observed. The GTV D(90) was covered by the 3.8 Gy isodose (95% of the prescription isodose of 4 Gy) and the doses received by the OARs varied between 4% and 43% of the prescription isodose for the V1 cc of spinal cord and eyeball, respectively. The only structure that could not be adequately spared was the skin overlying the tumoral lesion that received between 94% and 107% of the prescription isodose (1.0 and 0.5 cm(2) of skin, respectively). CONCLUSIONS: Intraoral mold-based HDR brachytherapy can be used to treat tumors involving the maxillary antrum provided that access is possible through a previous maxillectomy. A dose reduction of 4-43% in several OARs, such as the spinal cord, pituitary gland, optic chiasm, optic nerve, eyeball, and lens, is obtained.
Subject(s)
Brachytherapy/instrumentation , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/surgery , Maxillary Neoplasms/radiotherapy , Maxillary Neoplasms/surgery , Prosthesis Fitting/instrumentation , Aged , Combined Modality Therapy , Female , Humans , Maxillary Sinus/radiation effects , Maxillary Sinus/surgery , Treatment OutcomeABSTRACT
BACKGROUND: To determine the feasibility of combined perioperative high-dose-rate brachytherapy (PHDRB) and intermediate-dose external beam radiation therapy (EBRT) as an alternative to full-dose adjuvant EBRT in patients with unirradiated squamous cell cancer (SCC) of the oral cavity and oropharynx. METHODS AND MATERIALS: Forty patients were treated with surgical resection and PHDRB. PHDRB dose was 4Gy b.i.d.x4 (16Gy) for R0 resections and 4Gy b.i.d.x6 (24Gy) for R1 resections, respectively. External beam radiotherapy (45Gy in 25 fractions) was added postoperatively. Patients with Stage III, IVa tumors, and some recurrent cases received concomitant cisplatin-paclitaxel chemotherapy during EBRT. RESULTS: The rate of protocol compliance was 97.5%. Eleven patients (27.5%) developed RTOG Grade 3 or greater toxicity. Four patients (10%) presented complications requiring a major surgical procedure (RTOG 4), and one patient died of bleeding (RTOG 5). Three complications (7.5%) occurred in the perioperative period, and 8 (20.0%) occurred more than 3 months after the completion of the treatment program. Severe complications were more frequent in posteriorly located implants than in anterior implants (p=0.035). After a median follow-up of 50 months for living patients (range, 2.5-86.1+), the 7-year actuarial rates of local and locoregional control were 86% and 82%, respectively; and the 7-year disease-free survival and overall survival rates were 50.4% and 52.3%, respectively. CONCLUSIONS: PHDRB can be integrated into the management of patients with resected cancer of the oral cavity who are candidates to receive postoperative radiation or chemoradiation. The local control and toxicity rates were similar to those expected after standard chemoradiation. PHDRB was associated with high toxicity in posterior locations, and the scheduled PHDRB dose was shifted to the closest lower level.
Subject(s)
Brachytherapy/adverse effects , Carcinoma, Squamous Cell/radiotherapy , Mouth Neoplasms/radiotherapy , Oropharyngeal Neoplasms/radiotherapy , Adult , Aged , Brachytherapy/methods , Carcinoma, Squamous Cell/surgery , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Longitudinal Studies , Male , Middle Aged , Mouth Neoplasms/surgery , Oropharyngeal Neoplasms/surgery , Radiotherapy, AdjuvantABSTRACT
PURPOSE: To design an applicator for the treatment of tumors of the upper gum (UGCs) with high-dose-rate (HDR) brachytherapy. METHODS AND MATERIALS: A customized mold with four 6-Fr catheters was built. The two halves of the paired catheters form a functional loop without sharp curves. RESULTS: An adequate dose to the surface of the tumor is ensured. CONCLUSIONS: Mold-based HDR brachytherapy seems ideally suited for UGCs.
Subject(s)
Brachytherapy/instrumentation , Carcinoma, Squamous Cell/radiotherapy , Gingival Neoplasms/radiotherapy , Brachytherapy/methods , Dose-Response Relationship, Radiation , Equipment Design , Humans , Jaw, Edentulous , Middle Aged , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods , Radiotherapy, Adjuvant/methods , Radiotherapy, Computer-Assisted/methods , Treatment OutcomeABSTRACT
El melanoma es un tumor de marcada agresividad que se origina por la transformación maligna de los melanocitos de la capa basal de los epitelios de piel y menos frecuentemente de las mucosas. El melanoma primario de la cavidad oral es el tumor más maligno de los situados en la cabeza y cuello. Allí se localiza fundamentalmente en el maxilar superior (80 por ciento), sobre todo en la mucosa del paladar. Aunque su etiología es desconocida, en ocasiones asienta sobre melanosis preexistentes de largo tiempo de evolución, y permanece asintomático mucho tiempo hasta que se detecta como una masa pigmentada, a veces dolorosa. En la detección precoz del melanoma, juegan un papel decisivo los profesionales cuyo campo de acción es la cavidad oral, que deben localizar y biopsiar cualquier lesión sospechosa para descartar una posible transformación maligna .Una vez se ha manifestado tiende a invadir de forma precoz los tejidos adyacentes y a establecer metástasis linfáticas en los ganglios cervicales. En este momento el melanoma puede considerase como una enfermedad diseminada prácticamente incurable. El pronóstico del melanoma de la cavidad oral es muy malo, y el único tratamiento eficaz es la cirugía radical cuando todavía se encuentra localizado. Otras modalidades terapeúticas como la radioterapia, la quimioterapia o la inmunoterapia tienen en la actualidad una pobre contribución a la hora de mejorar la supervivencia de estos enfermoss enfermos (AU)